0.8621

5.92% 0.0482

Seres Therapeutics Inc (MCRB)

Overview News Price History Option Chain Financials Discussions Forecast

Seres Therapeutics Inc stock is traded at $0.8621, with a volume of 753.51K. It is up +5.92% in the last 24 hours and up +5.96% over the past month. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Previous Close:

$0.8139

Open:

$0.83

24h Volume:

753.51K

Relative Volume:

0.20

Market Cap:

$142.41M

Revenue:

$126.33M

Net Income/Loss:

$-82.68M

P/E Ratio:

-0.6952

EPS:

-1.24

Net Cash Flow:

$-79.98M

1W Performance:

+45.60%

1M Performance:

+5.96%

6M Performance:

-5.27%

1Y Performance:

-17.50%

1-Day Range:

$0.8045

$0.8795

1-Week Range:

$0.5406

$0.8845

52-Week Range:

$0.54

$2.05

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name

Seres Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

617 945 9626

Address

200 SIDNEY STREET, CAMBRIDGE, MA

Employee

233

Twitter

@SeresTX

Next Earnings Date

2024-10-31

Latest SEC Filings

MCRB's Discussions on Twitter

Compare MCRB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MCRB	0.8621	142.41M	126.33M	-82.68M	-79.98M	-1.24
VRTX	447.51	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.90	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.12	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.68	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.20	24.49B	3.30B	-501.07M	1.03B	11.54

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-26-23	Resumed	Oppenheimer	Outperform
Apr-21-23	Initiated	JP Morgan	Neutral
Jul-23-21	Downgrade	Goldman	Neutral → Sell
May-18-21	Resumed	Goldman	Neutral
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Aug-11-20	Upgrade	Jefferies	Hold → Buy
Apr-30-19	Initiated	Jefferies	Hold
Oct-22-18	Initiated	Chardan Capital Markets	Buy
Oct-13-17	Initiated	Oppenheimer	Outperform
Aug-04-17	Reiterated	H.C. Wainwright	Buy
Feb-01-17	Reiterated	FBR & Co.	Outperform
Aug-12-16	Reiterated	FBR Capital	Outperform
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Aug-01-16	Reiterated	H.C. Wainwright	Buy
Jul-29-16	Resumed	H.C. Wainwright	Buy
Mar-30-16	Initiated	FBR Capital	Outperform
Mar-03-16	Initiated	Guggenheim	Buy
Jan-25-16	Initiated	H.C. Wainwright	Buy
Oct-22-15	Upgrade	BofA/Merrill	Neutral → Buy
Jul-22-15	Initiated	Canaccord Genuity	Buy
Jul-21-15	Initiated	Goldman	Neutral
Jul-21-15	Initiated	Leerink Partners	Outperform

View All

Seres Therapeutics Inc Stock (MCRB) Latest News

Nov 20, 2024

Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 - Investing.com India

Nov 20, 2024

Seres Therapeutics Q3 2024 Earnings Preview - MSN

Nov 20, 2024

Nov 19, 2024

Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Rising Disease Prevalence Driving Revenue, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve

Nov 19, 2024

Seres Therapeutics chief legal officer sells shares worth $474 - Investing.com

Nov 19, 2024

Seres Therapeutics executive sells shares worth $397 By Investing.com - Investing.com UK

Nov 19, 2024

Nov 18, 2024

Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World

Nov 18, 2024

Nov 15, 2024

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Canaccord Genuity Group Reiterates "Buy" Rating for Seres Therapeutics (NASDAQ:MCRB) - MarketBeat

Nov 14, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024